|
US5126131A
(en)
|
1983-01-24 |
1992-06-30 |
The Johns Hopkins University |
Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
|
|
US6022544A
(en)
|
1983-01-24 |
2000-02-08 |
The John Hopkins University |
Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
|
|
US5370871A
(en)
|
1983-01-24 |
1994-12-06 |
The Johns Hopkins University |
Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
|
|
US5162515A
(en)
|
1990-01-16 |
1992-11-10 |
La Jolla Pharmaceutical Company |
Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
|
|
US5391785A
(en)
|
1990-01-16 |
1995-02-21 |
La Jolla Pharmaceutial Company |
Intermediates for providing functional groups on the 5' end of oligonucleotides
|
|
US5552391A
(en)
|
1990-01-16 |
1996-09-03 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
|
US5268454A
(en)
|
1991-02-08 |
1993-12-07 |
La Jolla Pharmaceutical Company |
Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
|
|
AU8869291A
(en)
|
1990-10-04 |
1992-04-28 |
University Of Virginia Alumni Patents Foundation, The |
Primate erythrocyte bound monoclonal antibody heteropolymers
|
|
IE922292A1
(en)
|
1991-07-15 |
1993-01-27 |
Jolla Pharma |
Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
|
|
EP1808183A3
(en)
|
1993-09-08 |
2009-07-01 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
CA2183535A1
(en)
|
1994-02-28 |
1995-08-31 |
Ronald P. Taylor |
Antigen-based heteropolymers and method for treating autoimmune diseases using the same
|
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
US5856464A
(en)
|
1995-06-07 |
1999-01-05 |
Lajolla Pharmaceutical Company |
Selective capping solution phase oligonucleotide synthesis
|
|
US5817752A
(en)
|
1996-06-06 |
1998-10-06 |
La Jolla Pharmaceutical Company |
Cyclic polypeptides comprising a thioether linkage and methods for their preparation
|
|
KR20000016414A
(ko)
|
1996-06-06 |
2000-03-25 |
와이즈먼 앤드루 |
Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
|
|
WO1998046523A1
(en)
|
1997-04-11 |
1998-10-22 |
Chiyoda Corporation |
Catalyst for preparation of synthesis gas and process for preparing carbon monoxide
|
|
EP1965213A3
(en)
|
1998-02-04 |
2009-07-15 |
Invitrogen Corporation |
Microarrays and uses therefor
|
|
DK1411075T3
(da)
|
1998-03-12 |
2008-10-27 |
Nektar Therapeutics Al Corp |
Fremgangsmåde til fremstilling af polymerkonjugater
|
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
|
MXPA01002580A
(es)
|
1998-09-10 |
2002-04-08 |
Univ Virginia |
Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
|
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
|
JP2002531531A
(ja)
|
1998-12-09 |
2002-09-24 |
ラ ホヤ ファーマシューティカル カンパニー |
循環している抗体を減少させるための方法および処方物
|
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
|
US20010010818A1
(en)
|
1998-12-09 |
2001-08-02 |
Engle Steven B. |
Methods and formulations for reducing circulating antibodies
|
|
KR20020022691A
(ko)
|
1999-06-08 |
2002-03-27 |
와이즈먼 앤드루 |
아미노옥시기를 포함하는 원자가 플랫폼 분자
|
|
HK1045944A1
(zh)
|
1999-11-28 |
2002-12-20 |
La Jolla Pharmaceutical Company |
基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物
|
|
AU2593901A
(en)
|
1999-12-23 |
2001-07-03 |
Elusys Therapeutics, Inc. |
Therapeutic use of particles displaying pathogen-specific binding moieties
|
|
EP1284752A4
(en)
|
2000-04-26 |
2004-08-18 |
Elusys Therapeutics Inc |
BISPECIFIC MOLECULES AND USES THEREOF
|
|
CN1434726A
(zh)
|
2000-06-08 |
2003-08-06 |
拉卓拉药物公司 |
包含高分子量聚环氧乙烷的多价平台分子
|
|
AU4155602A
(en)
|
2000-11-01 |
2002-06-18 |
Elusys Therapeutics Inc |
Method of producing biospecific molecules by protein trans-splicing
|
|
JP2004529945A
(ja)
|
2001-05-17 |
2004-09-30 |
ラ ホヤ ファーマシューティカル カンパニー |
Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
|
|
US20030114405A1
(en)
|
2001-08-13 |
2003-06-19 |
Linnik Matthew D. |
Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
|
|
AU2003303524A1
(en)
|
2002-12-27 |
2004-07-29 |
La Jolla Pharmaceutical Company |
Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
|
|
US20040258683A1
(en)
|
2003-03-30 |
2004-12-23 |
Linnik Matthew D. |
Methods of treating and monitoring systemic lupus erythematosus in individuals
|